The following is true of abciximab except:
A. It is a monoclonal antibody against GPIIb/IIIa
B. It inhibits platelet aggregation induced by a
variety of platelet agonists
C. It is antigenic
D. It is used to reduce the risk of restenosis in
patients undergoing PTCA
A. It is a monoclonal antibody against GPIIb/IIIa
B. It inhibits platelet aggregation induced by a
variety of platelet agonists
C. It is antigenic
D. It is used to reduce the risk of restenosis in
patients undergoing PTCA